<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1609245916
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GLUCOVANCE 5/500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GLIBENCLAMIDE,METFORMIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SANTE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SANTE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SANTE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Glucovance is<br />made up of two antidiabetic medicines, which belong to the groups of medicines called biguanide (metformin hydrochloride) and sulphonylurea (glibenclamide).<br />Insulin is a hormone that enables body tissues to take up glucose (sugar) from the blood and to use it for producing energy or to store it for future use. Patients with type 2 diabetes mellitus (i.e. non-insulin dependent diabetes) do not produce enough insulin in their pancreas or their body does not respond properly to the insulin it produces. This causes an increased level of glucose in the blood. Glucovance helps to reduce their blood sugar towards a normal level.<br />Glucovance is used for<br />the oral treatment (via the mouth) of type 2 diabetes mellitus in adult patients.<br />It is used to replace the combination of the two active substances of Glucovance (metformin hydrochloride and glibenclamide) given separately in patients previously treated with this combination, if the combination was effective in controlling the patients&rsquo; glucose level in the blood.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Glucovance<br />&bull; if you are allergic (hypersensitive) to metformin hydrochloride, glibenclamide or other sulphonamides or any of the other ingredients of Glucovance (listed in section 6).<br />&bull; if you have severely reduced kidney function<br />&bull; if you have liver function problems<br />&bull; if you suffer from type 1 diabetes mellitus (i.e. insulin-dependent)</p><p>&bull; if you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see &ldquo;Risk of lactic acidosis&rdquo; below) or ketoacidosis. Ketoacidosis is a condition in which substances called &#39;ketone bodies&#39; accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include stomach pain, fast and deep breathing, sleepiness or your breath developing an unusual fruity smell.<br />&bull; if you have a severe infection (for example an infection of the air passages or a urinary tract infection)<br />&bull; if you are dehydrated (for example due to persistent or severe diarrhoea, recurrent vomiting)<br />&bull; if you are treated for acute heart failure or have recently had a heart attack, have severe problems with your circulation (such as shock) or have breathing difficulties. This may lead to a lack in oxygen supply to tissue which can put you at risk for lactic acidosis (see &#39;Warnings and precautions&rsquo;).<br />&bull; if you suffer from porphyria (a rare, hereditary disease due to an enzyme deficiency causing the body to produce and excrete too much porphyrin, a component used to make the part of blood pigment that carries oxygen)<br />&bull; if you use miconazole (a medicine to treat certain yeast infections) even for local use<br />&bull; if you drink alcohol excessively (either every day or only from time to time)<br />&bull; if you are breast-feeding.</p><p>Make sure you ask your doctor for advice,<br />&bull; if you need to have an examination such as X-ray or scan involving the injection of contrast medicines that contain iodine into your bloodstream<br />&bull; if you need to have a surgery under general, spinal or epidural anaesthesia<br />You must stop taking Glucovance for a certain period of time before and after the examination or the surgery. Your doctor will decide whether you need any other treatment for this time. It is important that you follow your doctor&rsquo;s instructions precisely.<br />Warnings and precautions<br />Talk to your doctor before taking Glucovance.<br />Risk of lactic acidosis Glucovance may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see further information below), liver problems and any medical conditions in which a part of the body has reduced supply of oxygen (such as acute severe heart disease). If any of the above apply to you, talk to your doctor for further instructions. Stop taking Glucovance for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. Talk to your doctor for further instructions.<br />Stop taking Glucovance and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma.<br />Symptoms of lactic acidosis include:<br /> vomiting<br /> stomach ache (abdominal pain)<br /> muscle cramps<br /> a general feeling of not being well with severe tiredness<br /> difficulty in breathing<br /> reduced body temperature and heartbeat<br />Lactic acidosis is a medical emergency and must be treated in a hospital.</p><p>&nbsp;</p><p>If you need to have major surgery, you must stop taking Glucovance during and for some time after the procedure. Your doctor will decide when you must stop and when to restart your treatment with Glucovance.<br />Risk of Hypoglycaemia<br />&bull; if you experience symptoms of low blood sugar (hypoglycaemia). The warning signs may occur suddenly and can include cold sweat, cold and pale skin, dizziness, headache, rapid heartbeat, feeling sick, feeling very hungry, temporary changes in vision, drowsiness, unusual tiredness and weakness, nervousness or tremor, feeling anxious, feeling confused, difficulty in concentrating.<br />&bull; Patients aged 65 years and older are particularly sensitive to hypoglycaemic action of Glibenclamide and are therefore more at risk of hypoglycaemia. In the elderly, low blood sugar may be somewhat difficult to recognize. The initial dose and the maintenance dose of glibenclamide, must be set by your doctor carefully in order to avoid hypoglycemic reactions.<br />If you notice any of these signs:<br />- first eat glucose tablets or a high sugar snack (honey, sweets, biscuits, fruit juice),<br />- STOP taking this medicine IMMEDIATELY and TELL your DOCTOR straight away as you may need to be hospitalised to bring your blood glucose back under control, then rest.<br />General advice: Inform your family, friends and colleagues to turn you on your side and get medical aid straight away if you become unconscious. They should not give you any food or drink when you are unconscious. It could choke you.<br />A low blood sugar level might occur if:<br />- you eat too little or miss a meal<br />- your diet contains insufficient or unbalanced levels of sugar<br />- you drink alcohol<br />- you exercise more than usual<br />- you have liver, kidney or certain hormone problems<br />- the dosage of your medicine is too high<br />- you are an elderly person<br />- you are taking certain medicines and Glucovance at the same time (see section 2, &ldquo;Other medicines and Glucovance&rdquo;).<br />Discuss with your doctor whether Glucovance is the appropriate treatment for your diabetes if you often experience severe symptoms of low blood sugar or if you find it hard to recognise them.<br />&bull; if you suffer from any infectious illnesses such as flu, infection of the air passages or urinary tract infection.<br />&bull; if you have an inherited condition where your red blood cells don&rsquo;t produce enough of the enzyme G6PD (G6PD deficiency), taking Glucovance may cause your red blood cells to be destroyed too quickly (haemolytic anaemia). Tell your doctor if you have this condition, as Glucovance may not be suitable for you<br />&bull; Continue to follow any dietary advice your doctor has given you and get some regular exercise while you are taking this medicine.<br />&bull; Consult your doctor regularly to test your blood sugar levels and your kidney function.<br />Consult your doctor, if any of the above-mentioned situations applies to you and if you feel unsure about using this medicine.<br />During treatment with Glucovance, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function.</p><p>&nbsp;</p><p>Other medicines and Glucovance<br />While taking Glucovance, you must not use any of the following medicines:<br />&bull; miconazole even for local use (see section 2, &ldquo;Do not take Glucovance&rdquo;)</p><p>&nbsp;</p><p>&bull; If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Glucovance before or at the time of the injection. Your doctor will decide when you must stop and when to restart your treatment with Glucovance.<br />Tell your doctor if you are taking, have recently taken or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Glucovance. It is especially important to mention the following:<br />&bull; medicines which increase urine production (diuretics)<br />&bull; medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib)<br />&bull; certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II receptor antagonists)<br />&bull; beta-blockers (used to treat a variety of cardiovascular conditions, such as high blood pressure, and some other diseases)<br />&bull; beta-2 agonists (used to treat asthma, such as ritodrine, salbutamol or terbutaline)<br />&bull; bosentan (used to treat pulmonary hypertension)<br />&bull; corticosteroids and tetracosactide (a class of hormones used to treat a variety of conditions, e.g. severe inflammation of the skin or in asthma)<br />&bull; fluconazole (used to treat certain yeast infections)<br />&bull; chlorpromazine (a neuroleptic medicine, which affects how your brain works)<br />&bull; desmopressin (generally used to reduce urine production)<br />&bull; danazol (used to treat endometriosis, a condition where the tissue lining of the uterus is found outside the uterus)<br />&bull; bile acid sequestrants (cholesterol-lowering medicines used to reduce the amount of cholesterol in the blood)<br />&bull; medicines that may change the amount of Glucovance in your blood, especially if you have reduced kidney function (such as verapamil, rifampicin, cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, crizotinib, olaparib).<br />Special precautions may include self-monitoring of blood glucose, blood tests and modification of dosage.<br />Glucovance with alcohol<br />Avoid excessive alcohol intake while taking Glucovance since this may increase the risk of lactic acidosis (see section &ldquo;Warnings and precautions&rdquo;).<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. During pregnancy, diabetes should be treated with insulin. If you find out that you are pregnant while taking Glucovance, consult your doctor so that he/she may change your treatment.<br />You must not take Glucovance, if you are breast-feeding or if you are planning to breast-feed your baby.<br />Driving and using machines<br />Do not drive or use machines:<br />&bull; if your vision is blurred. This may happen at the beginning of the treatment because of a lower level of sugar in your blood.<br />&bull; if you feel that symptoms of low blood sugar begin to appear.</p><p>Important information about some of the ingredients of Glucovance<br />Each Glucovance tablet contains lactose. If your doctor has told you that you have an intolerance to certain sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dosage<br />Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br />Only adults may take this medicine.<br />Your doctor will adapt the dosage of your treatment depending on its effect on your blood tests. Continue to follow any dietary advice your doctor has given you. Glucovance cannot replace the benefits of a healthy lifestyle.<br />Have a regular meal schedule with a sufficient and balanced sugar intake. This will decrease the risk of low blood sugar.<br />The usual starting dose is equivalent to the individual doses of metformin hydrochloride and glibenclamide you received before being treated with Glucovance. If you are an elderly person, the usual starting dose is one tablet of Glucovance 500 mg/2.5 mg per day.<br />Maximum daily dose<br />For Glucovance 500 mg/2.5 mg: 6 tablets.<br />For Glucovance 500 mg/5 mg: 3 tablets. In exceptional cases, your doctor may prescribe 4 tablets.<br />Dosage adjustment in elderly patients<br />Take special care if you are an elderly person. The dose of Glucovance will be carefully increased depending on your blood sugar levels and your kidney function. Make sure that you consult your doctor regularly.<br />Dosage adjustment in patients with reduced kidney function<br />If you have reduced kidney function, your doctor may prescribe a lower dose.<br />Administration<br />Take the tablets with a meal. Swallow each tablet whole with a glass of water. Do not crush or chew them before swallowing.<br />Take the tablets<br />&bull; once a day, in the morning (breakfast) if you take 1 tablet per day<br />&bull; twice a day, in the morning (breakfast) and evening (dinner) if you take 2 or 4 tablets per day<br />&bull; three times a day, in the morning (breakfast), noon (lunch) and evening (dinner), if you take 3, 5 or 6 tablets per day.<br />Your doctor will tell you how to take Glucovance if you have to take it in combination with a cholesterol-lowering medicine (bile acid sequestrant). Glucovance must be taken at least 4 hours prior to a cholesterol-lowering medicine (bile acid sequestrant).<br />If you take more Glucovance than you should<br />If you have taken more Glucovance tablets than you should have, you may experience lactic acidosis or low blood sugar (for symptoms of lactic acidosis and low blood sugar, see section 2, &ldquo;Warnings and precaution&rdquo;). TALK to your DOCTOR IMMEDIATELY.<br />If you forget to take Glucovance<br />Do not take a double dose to make up for a forgotten dose. Take the next dose at the usual time.<br />If you stop taking Glucovance<br />There are usually no side effects when you stop taking this medicine. However, as your diabetes is not treated any more, complications due to a lack of treatment can occur.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects were observed in clinical studies or in routine patient management.<br />Glucovance may cause a very rare (may affect up to 1 user in 10,000), but very serious side effect called lactic acidosis (see section &ldquo;Warnings and precautions&rdquo;). If this happens you must stop taking Glucovance and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.<br />Vision disorders: When you start taking this medicine, it may disturb your vision due to a lower level of sugar in your blood. However, this reaction usually disappears after a while.<br />Low blood sugar: For symptoms of low blood sugar, see section 2, &ldquo;Warnings and precautions&rdquo;.<br />Very common side effects (may affect more than 1 in 10 people)<br />&bull; gastrointestinal disorders such as nausea, vomiting, diarrhoea, bellyache and loss of appetite.<br />These side effects occur most frequently after starting therapy. It helps if you spread the doses over the day and if you take the tablets with a meal. Should these symptoms continue, STOP taking this medicine and CONSULT your DOCTOR.<br />Common side effects (may affect up to 1 in 10 people)<br />&bull; taste disturbance<br />Uncommon side effects (may affect up to 1 in 100 people)<br />&bull; abnormal urea and creatinine levels in the blood, which show changes in the way the kidneys are working.<br />&bull; a crisis of certain forms of porphyria (porphyria hepatica or porphyria cutanea; for an explanation of porphyria, see section 2, &ldquo;Do not take Glucovance&rdquo;) may occur in patients with certain enzyme deficiency.<br />Rare side effects (may affect up to 1 in 1.000 people)<br />&bull; reduction in the number of white blood cells, which makes infections more likely<br />&bull; reduction in blood platelets which increases risk of bleeding or bruising<br />&bull; skin reactions including itching, hives, skin rash<br />Very rare side effects (may affect up to 1 in 10.000 people)<br />&bull; lactic acidosis (see section &ldquo;Warning and precautions&rdquo;).<br />&bull; severe reduction in the number of white blood cells (agranulocytosis), anaemia due to a too extensive breakdown of the red blood cells (haemolytic anaemia), lack or insufficient number of new blood cells produced by the bone marrow (bone marrow aplasia) and very severe reduction in the number of blood cells (pancytopenia; this can make the skin look pale, can cause weakness or breathlessness, can increase the risk of bleeding or bruising or make infections more likely)<br />&bull; abnormalities in liver function tests or inflammation of the liver (hepatitis; this can cause tiredness, loss of appetite, weight loss, with or without yellowing of the skin or whites of the eyes). If this happens to you, stop taking Glucovance and talk to your doctor.<br />&bull; excessive skin sensitivity to sun, serious allergic reactions of the skin or blood vessels<br />&bull; intolerance to alcohol (with symptoms such as general feeling of discomfort, redness of face, rapid heartbeat)<br />&bull; low level of sodium, which can cause tiredness and confusion, muscle twitching, fits or coma<br />&bull; decreased vitamin B12 levels in the blood</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C.<br />Do not use the drug after the expiry date printed on the package.<br />Keep out of the reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>A- What Glucovance contains<br />&bull; The active substances are metformin hydrochloride and glibenclamide.<br />&bull; One film-coated tablet of Glucovance 500 mg/2.5 mg contains 500 mg metformin hydrochloride corresponding to 390 mg metformin base and 2.5 mg glibenclamide.<br />&bull; One film-coated tablet of Glucovance 500 mg/5 mg contains 500 mg metformin hydrochloride corresponding to 390 mg metformin base and 5 mg glibenclamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                B- Shelf life
36 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Produced &amp; Marketed by MERCK SANTE s.a.s<br />37, Rue Saint Romain<br />69379 LYON CEDEX 08<br />Packed by RIYADH PHARMA<br />Medical and Cosmetic Products Co. Ltd.<br />Riyadh, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                17 April 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>مصنوع من دوائین مضادین للسكري، ینتمیان لمجموعتي أدویة تعرف بثنائیات الغوانید (ھیدروكلورید المیتفورمین) والسلفونیل یوریا<br />(غلیبینكلامید).<br />الأنسولین ھو ھرمون یساعد أنسجة الجسم على استخلاص الجلوكوز (السكر) من الدم واستخدامھ في تولید الطاقة أو تخزینھا للاستخدام<br />المستقبلي. لا ینتج المرضى المصابین بمرض السكري من النوع الثاني (ما یعرف بمرض السكري غیر المعتمد على الأنسولین) كمیة<br />كافیة من الأنسولین في البنكریاس أو لا تستجیب أجسامھم بشكل مناسب للأنسولین الذي ینتجھ. یؤدي ذلك إلى ارتفاع مستوى الجلوكوز في<br />الدم. یساعد جلوكوفانس على تقلیل سكر الدم لدیھم والوصول بھ للمستوى الطبیعي.<br />یسُتخدم جلوكوفانس في<br />العلاج الفموي (عبر الفم) لمرض السكري من النوع الثاني لدى المرضى البالغین.<br />وھو یستخدم كبدیل عن تولیفة من مادتین من الجلوكوفانس (ھیدروكلورید المیتفورمین وغلیبینكلامید) الذي یتم إعطاء كل منھما على حدا<br />للمرضى الذین خضعوا في الماضي للعلاج بھذه التولیفة، إذا ثبت أن التولیفة كانت فعالة في السیطرة على مستوى الجلوكوز في الدم لدى<br />المرضى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تأخذ جلوكوفانس<br />&bull; إذا كنت مصاباً بحساسیة (فرط تحسس) تجاه ھیدروكلورید المیتفورمین، أو الغلیبینكلامید، أو أنواع أخرى من السولفوناماید أو<br />.( أي من مكونات جلوكوفانس (المدرجة في القسم 6<br />&bull; إذا كان لدیك قصور شدید في وظائف الكلى<br />&bull; إذا كانت لدیك مشكلات في وظیفة الكبد<br />&bull; إذا كنت تعاني من السكري النوع الأول (أي المعتمد على الأنسولین)</p><p>&bull; إذا كنت مصاباً بمرض السكري وكان مرضك غیر خاضع للسیطرة، فرط سكر الدم (ارتفاع الجلوكوز في الدم)، غثیان، قيء،<br />إسھال، نقص سریع في الوزن، الحُماض اللبني (انظر &quot;خطر الحُماض اللبني&quot; أدناه) أو الحماض الكیتوني. الحماض الكیتوني ھي حالة<br />تتراكم فیھا المواد المعروفة باسم &quot;الأجسام الكیتونیة&quot; والتي یمكن أن تؤدي إلى مرحلة ما قبل الغیبوبة السكریة. تتضمن الأعراض<br />&bull; ألم البطن، تنفس سریع وعمیق، نعاس أو اكتساب نفسك لرائحة فاكھیة غیر معتادة.<br />&bull; إذا كنت مصاباً بعدوى حادة (على سبیل المثال عدوى المسالك الھوائیة أو عدوى المسالك البولیة)<br />&bull; إذا كنت مصاباً بالجفاف (على سبیل المثال بسبب إسھال مستمر أو شدید، قيء متكرر)<br />&bull; إذا كنت تعالج من فشل قلبي حاد أو تعرضت لآزمة قلبیة مؤخرًا، كنت تعاني من مشكلات في دورتك الدمویة (مثل صدمة) أو<br />لدیك صعوبات في التنفس. قد یؤدي ذلك لنقص في ما تحصل علیھ الأنسجة من إمدادات الأكسجین والذي یمكن أن یعرضك للخطر<br />الحُماض اللبني (انظر &quot;تحذیرات واحتیاطات&quot;).<br />&bull; إذا كنت تعاني من البورفیریا (مرض وراثي نادر یحدث بسبب نقص في الإنزیم الذي یدفع الجسم لإنتاج وإفراز كمیة كبیرة<br />للغایة من البرُفیرین، وھو مكون یسُتخدم في تصنیع جزء من صبغة الدم، وھو الجزء الذي یحمل الأكسجین)<br />&bull; إذا كنت تستخدم مِیكُونازول (وھو عقار لعلاج أنواع معینة من العدوى الفطریة) حتى ولو كنت تستخدمھ موضعیاً<br />&bull; إذا كنت تشرب كمیات مفرطة من الكحول (سواء كل یوم أو من حین لآخر)<br />&bull; إذا كنتِ ترضعین.<br />تأكدي من طلبك لمشورة الطبیب،<br />&bull; إذا كنت بحاجة للخضوع لفحص مثل التصویر بالأشعة السینیة أو تصویر یتضمن حقن أدویة تباین تحتوي على الیود في مجرى<br />دمك<br />&bull; إذا كنت بحاجة للخضوع لجراحة تحت تخدیر عام، أو فقري أو فوق الجافیة<br />یجب أن تتوقف عن أخذ جلوكوفانس لمدة معینة قبل وبعد الفحص أو الجراحة. سیقرر طبیبك ما إذا كنت بحاجة لأي علاج آخر حینھا.<br />من المھم أت تتبع تعلیمات طبیبك بدقة.<br />تحذیرات واحتیاطات<br />تحدث مع طبیبك قبل أن تأخذ جلوكوفانس.<br />خطر الحُماض اللبني<br />قد یسبب جلوكوفانس آثرًا جانبیاً نادرًا للغایة ولكنھ خطیرًا للغایة یعرف بالحُماض اللبني، خاصة إذا كانت كلیتاك لا تعملان بشكل جید.<br />یزداد خطر الإصابة بالحُماض اللبني أیضًا في حالة الإصابة بمرض السكري غیر الخاضع للسیطرة، حالات عدوى خطیرة، الصیام لمدة<br />طویلة أو تناول الكحول، الجفاف (لمزید من المعلومات انظر أدناه)، مشكلات في الكبد وأي حالات طبیة یحصل فیھا جزء من الجسم على<br />إمداد قلیل من الأكسجین (مثل مرض قلبي حاد وشدید). إذا انطبق علیك أي من الوارد أعلاه، تحدث مع طبیبك للحصول على مزید من<br />التعلیمات.<br />توقف عن استعمال جلوكوفانس لفترة قصیرة إذا كنت مصاباً بحالة قد تكون مرتبطة بالجفاف (فقد كبیر في سوائل الجسم) مثل القيء<br />الشدید، الإسھال، الحمى، التعرض للحرارة في حالة شربك لكمیة من السوائل أقل من المعتاد. تحدث مع طبیبك للحصول على مزید من<br />التعلیمات.<br />توقف عن أخذ جلوكوفانس واتصل بالطبیب أو بأقرب مستشفى في الحال إذا تعرضت لبعض من أعراض الحُماض اللبني، فقد تؤدي ھذه<br />الحالة إلى غیبوبة.<br />تتضمن أعراض الحُماض اللبني:<br />&bull; القيء<br />&bull; ألم المعدة (ألم البطن)<br />&bull; التشنجّات العضلیة<br />&bull; إحساس عام بأنك لست عل ما یرام مع تعب شدید<br />&bull; صعوبة في التنفس<br />&bull; انخفاض حرارة الجسم وضربات القلب</p><p>یمثل الحُماض اللبني حالة طوارئ طبیة، ویجب علاجھ في المستشفى.<br />إذا كنت بحاجة للخضوع لجراحة كبرى علیك أن تتوقف عن أخذ جلوكوفانس أثناء الإجراء وبعده لبعض الوقت. سیقرر طبیبك متى یتعین<br />علیك أن تتوقف ومتى تبدأ في العلاج بجلوكوفانس من جدید.<br />خطر نقص الجلوكوز في الدم<br />&bull; إذا تعرضت لأعراض انخفاض سكر الدم (نقص السكر في الدم). قد تظھر علامات التحذیر فجأة وقد تتضمن مل مما یلي: عرق<br />برد، جلد بارد وشاحب، دوخة، صداع، ضربات قلب سریعة، شعور بالغثیان، شعور بجوع شدید، تغیرات مؤقتة في الرؤیة، نعاس، تعب<br />وضعف غیر معتادین، عصبیة أو رُعاشٌ، شعور بالقلق، شعور بالارتباك، صعوبة في التركیز.<br />&bull; المرضى ممن یبلغون 65 عامًا أو أكبر حساسون بشكل خاص لنقص الجلوكوز في الدم بسبب الغلیبینكلامید لذا ھم معرضون<br />لخطر نقص الجلوكوز في الدم بشكل أكبر. اكتشاف نقص سكر الدم لدى كبار السن قد یكون صعباً بعض الشيء. یجب أن یضبط طبیبك<br />الجرعة الأولیة وجرعة الصیانة الخاصة بغلیبینكلامید بدقة لتلافي ردود الفعل الخاصة بنقص الجلوكوز في الدم.<br />إذا لاحظت أي من ھذه الأعراض:<br />- تناول أولا أقراص الجلوكوز أو وجبة خفیفة تحتوي على قدر عالي من السكر (عسل، حلوى، بسكویت، عصیر فاكھة)،<br />- توقف عن أخذ ھذا العقار فورًا وأخبر طبیبك في الحال فقد تحتاج إلى دخول المستشفى لاستعادة السیطرة على الجلوكوز في الدم لدیك،<br />ثم خذ قسطًا من الراحة.<br />نصیحة عامة: أخبر أسرتك، أصدقائك، زملائك لإمالتك على جانبك وطلب المساعدة الطبیة لك في الحال إذا أوشكت على فقد وعیك. یجب<br />ألا یعطوك أي طعام أو شراب حینما تكون غائباً عن الوعي. فقد یؤدي إلى اختناقك.<br />قد یحدث انخفاض في مستوى السكر في الدم:<br />- إذا كنت تأكل كمیات قلیلة للغایة أو فوّت وجبة<br />- إذا كان نظامك الغذائي یحتوي على مستویات غیر كافیة أو غیر متوازنة من السكر<br />- إذا كنت تشرب كحولیات<br />- إذا كنت تمارس التدریبات الریاضیة بقدر أكبر من المعتاد<br />- إذا كانت لدیك مشكلات ھرمونیة معینة في الكبد، أو الكلى، أو في ھرمون بعینھ<br />- جرعة العقار الخاص بك مرتفعة للغایة<br />- كنت شخصًا مسناً<br />- تأخذ أدویة معینة وجلوكوفانس في نفس الوقت (انظر القسم 2، &quot;الأدویة الأخرى وجلوكوفانس&quot;).<br />ناقش مع طبیبك ما إذا كان جلوكوفانس علاجًا مناسباً لمرض السكري لدیك إذا كنت تتعرض دومًا لأعراض انخفاض سكر الدم الشدیدة أو<br />إذا كنت تجد صعوبة في اكتشافھا.<br />&bull; إذا كنت تعاني من أي أمراض معدیة مثل الإنفلونزا، عدوى المسالك الھوائیة أو عدوى المسالك البولیة.<br />قد یؤدي أخذ جلوكوفانس ،(G6PD نقص ) G6PD &bull; إذا كانت لدیك حالة وراثیة تؤدي لعجز خلایا دمك الحمراء عن إنتاج إنزیم<br />إلى تعرض خلایا دمك الحمراء للتدمیر بسرعة كبیرة للغایة (فقر الدم الانحلالي). أخبر طبیبك إذا كنت تعاني من ھذه الحالة، فقد یكون<br />جلوكوفانس غیر مناسب لك<br />&bull; استمر في اتباع أي نصیحة غذائیة قدمھا لك طبیبك وقم بأداء بعض التدریبات الریاضیة بینما تأخذ ھذا الدواء.<br />&bull; راجع طبیبك بانتظام لاختبار مستویات سكر الدم لدیك ووظیفة الكلى لدیك.<br />استشر طبیبك، إذا كانت أي من المواقف المذكورة أعلاه تنطبق علیك أو إذا كنت غیر متأكد مما إذا كان یمكنك استخدام ھذا الدواء.<br />أثناء العلاج بجلوكوفانس، سیتحقق طبیبك من وظیفة كلیتیك مرة واحدة على الأقل في السنة أو أكثر إذا كنت مسناً و/أو إذا ازدادت وظیفة<br />كلیتیك سوءًا.</p><p>&nbsp;</p><p>&nbsp;</p><p>الأدویة الأخرى وجلوكوفانس<br />أثناء أخذ جلوكوفانس، یجب ألا تأخذ أي من الأدویة التالیة:<br />&bull; مِیكُونازول حتى إذا كان للاستخدام الموضعي (انظر القسم 2، &quot;لا تأخذ جلوكوفانس&quot;)<br />&bull; إذا كنت بحاجة للحقن بوسیطة تباین تحتوي على الیود في مجرى دمك، على سبیل المثال في سیاق مثل التصویر بالأشعة<br />السینیة أو إجراء تصویر، یجب أن تتوقف عن أخذ جلوكوفانس قبل أو أثناء الحقن. سیقرر طبیبك متى یتعین علیك أن تتوقف ومتى تبدأ في<br />العلاج بجلوكوفانس من جدید.<br />أخبر طبیبك إذا كنت تتناول أدویة أخرى أو تناولتھا مؤخرًا أو ربما تتناولھا في المستقبل. قد تحتاج إلى مزید من اختبارات الجلوكوز في<br />الدم ووظائف الكلى، أو قد یحتاج طبیبك لضبط جرعة جلوكوفانس. من الأھمیة بمكان ذكر ما یلي:<br />&bull; الأدویة التي تزید إنتاج البول (مدرات البول)<br />،COX- ومثبطات 2 &quot;NSAID&quot; &bull; الأدویة المستخدمة في علاج الألم والالتھاب (الأدویة غیر الستیرودیة المضادة للالتھابات<br />مثل ایبوبروفین وسیلكوكسیب)<br />(II و وناھضات مستقبلات الأنجیوستین ACE &bull; أدویة معینة لعلاج ارتفاع ضغط الدم (مثبطات<br />&bull; حاصرات مستقبلات بیتا (تسُتخدم لعلاج العدید من الحالات القلبیة الوعائیة، مثل ارتفاع ضغط الدم، وبعض الأمراض<br />الأخرى)<br />&bull; ناھضات بیتا 2 (تسُتخدم لعلاج الربو، مثل الریتودرین ، أو السالبتامول، أو التیربوتالین)<br />&bull; بوسنتان (یسُتخدم عادة لعلاج فرط ضغط الدم الرئوي)<br />&bull; الكورتیكوستیرویدات والتتراكوساكتیدات (فئة من الھرمونات تسًتخدم لعلاج العدید من الحالات، مثل التھاب الجلد الشدید أو<br />الربو)<br />&bull; فلوكونازول (یسُتخدم لعلاج حالات معینة من العدوى الفطریة)<br />&bull; كلوربرومازین (دواء مضاد للذھان، والذي یؤثر على الطریقة التي یعمل بھا مخك)<br />&bull; دیزمُوبرِیسِین (یسًتخدم عادة لتقلیل إنتاج البول)<br />&bull; دانازول (یسًتخدم لعلاج الانتباذ البطاني الرحمي، وھي حالة تكون فیھا البطانة النسیجیة للرحم خارج الرحم)<br />&bull; منحیات حامض الصفراء (الأدویة المخفضة للكولیسترول المستخدمة في تقلیل كمیة الكولیسترول في الدم)<br />&bull; الأدویة التي قد تغیر من كمیة جلوكوفانس في دمك، خاصة إذا كنت تعاني من قصور في وظیفة الكلى (مثل فیرابامیل،<br />وریفامبیسین، وسیمیتیدین، ودولوتیغرافیر، ورانولازین، وتریمیثوبرایم، وفاندیتانیب، وإیسافوكونازول، وكریزوتینیب،<br />وأولاباریب).<br />قد تتضمن الاحتیاطات الخاصة المراقبة الذاتیة للجلوكوز في الدم، واختبارات الدم، وتعدیل الجرعة.<br />جلوكوفانس مع الكحول<br />تجنب شرب كمیات مفرطة من الكحول أثناء أخذ جلوكوفانس نظرًا لأن ذلك قد یزید من خطر الحُماض اللبني (انظر القسم &quot;تحذیرات<br />واحتیاطات&quot;).<br />الحمل والإرضاع<br />إذا كنتِ حاملا أو مرضعة أو تعتقدین أنكِ قد تكوني حاملا أو تخططین لإنجاب طفل، فاحرصي على طلب المشورة من طبیبك قبل تناول<br />ھذا الدواء. أثناء الحمل، یجب علاج السكري بالأنسولین. إذا اكتشفتِ أنكِ حامل بینما تأخذین جلوكوفانس، استشیري طبیبك بحیث یمكنھ<br />تغییر علاجك.<br />إذا كان یجب ألا تأخذین جلوكوفانس، إذا كنت ترضعین أو إذا كنتِ تخططین لإرضاع طفلكِ.<br />القیادة واستعمال الآلات<br />لا تقود أو تستعمل الآلات:<br />&bull; إذا كنت تعاني من عدم وضوح الرؤیة. قد یحدث ذلك في بدایة العلاج نظرًا لانخفاض مستوى السكر في دمك.<br />&bull; إذا شعرت أن أعراض انخفاض سكر الدم بدأت في الظھور.</p><p>&nbsp;</p><p>معلومات مھمة حول بعض مكونات جلوكوفانس<br />یحتوي كل قرص من أقراص جلوكوفانس على اللاكتوز. إذا أخبرك طبیبك أنك غیر قادر على تحمل بعض السكریات، اتصل بطبیبك قبل<br />أخذ ھذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>الجرعة<br />استعمل ھذا العقار بالضبط كما أشار علیك طبیبك تمامًا. یجب علیكِ استشارة طبیبك أو الصیدلي إذا كنتِ غیر متأكد.<br />یمكن فقط للبالغین أخذ ھذا الدواء.<br />سیعدل طبیبك جرعة علاجك بناء على تأثیره على اختبارات الدم الخاصة بك. استمر في اتباع أي نصیحة غذائیة یقدمھا لك طبیبك. لا<br />یمكن أن یحل جلوكوفانس محل المزایا الخاصة بنمط الحیاة الصحیة.<br />احرص على وضع جدول وجبات منتظمة یحتوي على قدر كافِ ومتوازن من السكریات. سیقلل ذلك من خطر انخفاض سكر الدم.<br />جرعة البدایة المعتادة مساویة للجرعات الفردیة من ھیدروكلورید المیتفورمین وغلیبینكلامید التي تتلقاھا قبل الخضوع للعلاج<br />بجلوكوفانس. إذا كنت شخصًا مسناً، فأن جرعة البدایة المعتادة ھي قرص واحد من جلوكوفانس 500 ملغ/ 2.5 ملغ، في الیوم.<br />الجرعة الیومیة القصوى<br />بالنسبة لجلوكوفانس 500 ملغ/ 2.5 ملغ: 6 أقراص.<br />بالنسبة لجلوكوفانس 500 ملغ/ 5 ملغ: 3 أقراص. في الحالات الاستثنائیة، قد یصف لك طبیبك 4 أقراص.<br />تعدیل الجرعة للمرضى المسنین<br />توخى الحذر بشكل خاص إذا كنت شخصًا مسناً. ستتم زیادة جرعة جلوكوفانس بحرص بناء على مستویات سكر الدم ووظیفة كلیتیك. تأكد<br />من استشارتك لطبیبك بانتظام.<br />تعدیل الجرعة لدى المرضى المصابین بقصور في وظیفة الكلى<br />إذا كنت تعاني من قصور في وظیفة الكلى، قد یصف لك طبیبك جرعة أقل.<br />تناول الدواء<br />خذ الأقراص برفقة وجبة. ابتلع كل قرص كاملا مع كوب من المیاه. لا تسحق أو تمضغ القرص قبل ابتلاعھ.<br />خذ الأقراص<br />&bull; مرة یومیاً، في الصباح (الفطور) إذا أخذت قرصًا واحدًا في الیوم<br />&bull; مرتان في الیوم، في الصباح (الفطور) والمساء (العشاء) إذا كنت تأخذ قرصین أو 4 أقراص في الیوم<br />&bull; ثلاث مرات في الیوم، في الصباح (الفطور)، والظھر (الغذاء)، والمساء (العشاء) إذا كنت تأخذ 3، أو 5، أو 6 أقراص في<br />الیوم.<br />سیخبرك طبیبك كیف تأخذ جلوكوفانس إذا كنت تأخذه برفقة عقار مخفض للكولیسترول (منحي حامض الصفراء). یجب أخذ جلوكوفانس<br />قبل العقار المخفض للكولیسترول (منحي حامض الصفراء) ب 4 ساعات على الأقل.<br />إذا أخذت كمیة أكبر من جلوكوفانس عما یجب أن تأخذه<br />إذا أخذت كمیة أكبر من أقراص جلوكوفانس عما یجب أن تأخذه، قد تتعرض للإصابة بالحُماض اللبني أو انخفاض سكر الدم (لمعرفة<br />الأعراض الخاصة بالحُماض اللبني وانخفاض سكر الدم، انظر القسم 2 &quot;تحذیرات واحتیاطات&quot;). تحدث مع طبیبك في الحال.<br />إذا نسیت تناول جلوكوفانس<br />لا تتناول جرعة مزدوجة لتعویض الجرعة التي نسیتھا. خذ الجرعة التالیة في موعدھا المعتاد.<br />إذا توقفت عن أخذ جلوكوفانس<br />لا توجد عادة آثار جانبیة حینما تتوقف عن أخذ ھذا الدواء. ومع ذلك، نظرًا لعدم وجود علاج للسكري لدیك، قد تحدث مضاعفات بسبب<br />نقص العلاج.<br />إذا راودتك أيّ أسئلة إضافیة حول استعمال ھذا المنتج، فاطرحھا على طبیبك أو الصیدلي.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثلھ مثل كافة العقاقیر، قد یسبب ھذا العقار آثار اً جانبیة على الرغم من أنھا لا تصیب جمیع المرضى. تمت ملاحظة الآثار الجانبیة التالیة<br />في الدراسات السریریة أو في الإدارة الروتینیة للمرضى.<br />قد یتسبب جلوكوفانس في آثار جانبیة نادرة للغایة (ما یصل لمستخدم واحد من أصل 10000 ) ولكنھا خطیرة للغایة تسمى الحُماض اللبني<br />(انظر القسم &quot;تحذیرات واحتیاطات&quot;). إذا حدث ذلك فتوقف عن أخذ جلوكوفانس واتصل بالطبیب أو بأقرب مستشفى في الحال ، فقد<br />یؤدي الحُماض اللبني إلى غیبوبة.<br />اضطرابات الرؤیة: حینما تبدأ في أخذ ھذا الدواء، قد یؤثر على رؤیتك بالسلب نظرًا لانخفاض مستوى السكر في دمك. ومع ذلك، عادة ما<br />یختفي رد الفعل ھذا بعد فترة.<br />انخفاض سكر الدم: لمعرفة أعراض انخفاض سكر الدم، انظر القسم 2، &quot;تحذیرات واحتیاطات&quot;.<br />آثار جانبیة شائعة جدًا (قد تؤثر على مریض من كل 10 مرضى)<br />&bull; اضطرابات الجھاز الھضمي مثل الغثیان، والقيء، والإسھال، وألم البطن، وفقدان الشھیة. تحدث ھذه الآثار الجانبیة بوتیرة أكبر<br />بعد بدء العلاج. توزیع الجرعات على مدار الیوم قد یساعد كذلك إذا أخذت الأقراص بعد وجبة. إذا استمرت ھذه الأعراض،<br />توقف عن أخذ ھذا العقار واستشر طبیبك.<br />آثار جانبیة شائعة (قد تؤثر على مریض من أصل 10 مرضى)<br />&bull; اضطراب حاسة الذوق<br />آثار جانبیة غیر شائعة (قد تؤثر على مریض من كل 100 مریضٍ)<br />&bull; مستویات غیر طبیعیة من الیوریا والكریاتینین في الدم، وھو ما یدل على حدوث تغیرات في طریقة عمل الكلیتین.<br />&bull; قد تحدث أزمة خاصة ببعض أشكال البورفیریا (البورفیریا الكبدیة أو البورفیریا الجلدیة الآجلة؛ للاطلاع على شرح خاص<br />بالبورفیریا، انظر القسم 2 &quot;لا تأخذ جلوكوفانس&quot;) لدى المرضى المصابین بنقص إنزیمي معین.<br />آثار جانبیة نادرة (قد تؤثر على مریض من أصل 1000 مرضى)<br />&bull; نقص عدد خلایا الدم البیضاء، وھو ما یزید من قابلیة الإصابة بعدوى<br />&bull; نقص في الصفائح الدمویة یزید من خطر النزیف أو التكدم<br />&bull; ردود فعل جلدیة تتضمن الجة، الشرى، طفح جلدي<br />آثار جانبیة نادرة جد ا (قد تصیب حتى 1 من أصل 10000 شخص)<br />&bull; الحماض اللبني (انظر &quot;تحذیرات واحتیاطات&quot;).<br />&bull; انخفاض حاد في عدد خلایا الدم البیضاء (ندرة الحبیبات)، فقر الدم نتیجة للتكسیر الشدید لخلایا الدم الحمراء (فقر الدم<br />الانحلالي)، نقص أو وجود عدد غیر كاف من خلایا الدم الحمراء الجدیدة التي ینتجھا نخاع العظم (عدم تنسج نخاع العظم)<br />وانخفاض حاد في عدد خلایا الدم (قلة الكریات الشاملة: قد یؤدي ذلك لشحوب الجلد أو التكدم أو یزید إمكانیة الإصابة بعدوى)<br />&bull; شذوذات في اختبارات وظائف الكبد أو التھاب الكبد (الالتھاب الكبدي؛ یمكن أن یؤدي ذلك للشعور بالتعب، وفقدان الشھیة،<br />خسارة الوزن، مع إصفرار أو عدم إصفرار الجلد أو بیاض العینین). إذا حدث لك ذلك، توقف عن أخذ جلوكوفانس وتحدث مع<br />طبیبك.<br />&bull; فرط حساسیة الجلد للشمس، وردود فعل تحسسیة شدیدة تصیب الجلد أو الأوعیة الدمویة<br />&bull; عدم تحمل الكحول (مع أعراض مثل شعور عام بالضیق، احمرار الوجھ، ضربات القلب السریعة)<br />&bull; انخفاض مستوى الصودیوم، یؤدي للتعب وارتباك، انتفاض العضلات، نوبات، غیبوبة<br />&bull; انخفاض مستویات فیتامین ب 12 في الدم</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>5. كیفیة تخزین جلوكوفانس<br />یحُفظ في درجة حرارة أقل من 30 درجة مئویة.<br />لا تستخدم العقار بعد تاریخ انتھاء الصلاحیة المطبوع على العبوة.<br />یحُفظ بعید اً عن متناول الأطفال:</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>6. محتویات العلُبة<br />أ- ما الذي یحتوي علیھ جلوكوفانس<br />&bull; المواد الفعالة ھي ھیدروكلورید المیتفورمین وغلیبینكلامید.<br />&bull; یحتوى كل قرص مغلف واحد من جلوكوفانس ملغ/ 2.5 ملغ على 500 ملغ من ھیدروكلورید المیتفورمین تعادل<br />390 ملغ من أساس المیتفورمین و/ 2.5 ملغ من غلیبینكلامید.<br />&bull; یحتوى كل قرص مغلف واحد من جلوكوفانس 500 ملغ/ 5 ملغ على 500 ملغ من ھیدروكلورید المیتفورمین تعادل<br />390 ملغ من أساس المیتفورمین و/ 5 ملغ من غلیبینكلامید.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ب- تاریخ انتھاء الصلاحیھ<br />36 شھرا من تاریخ انتھاء العلبھ</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>انتاج وتسویق شركة میرك سانتي اس ایھ اس<br />37 شارع سانت رومن , 69379 لیون سدیكس 08<br />تعبئة الریاض فارما , شركة المنتجات الطبیھ والتجمیلیھ المحدوده<br />الریاض , المملكھ العربیة السعودیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            17 ابريل 2019 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                GLUCOVANCE 500 mg/5 mg, film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 500 mg metformin hydrochloride, equivalent to 390 mg metformin, and 5 mg glibenclamide.
Excipient(s) with known effect: lactose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Yellow capsule-shaped, biconvex film-coated tablets with '5' engraved on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of type 2 diabetes in adults, as replacement for previous combination therapy with metformin and Glibenclamide in patients whose glycaemia is stable and well-controlled.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Oral route.<br />For use in adults only.</p><p>General:<br />As for all hypoglycaemic agents, the dosage should be adapted according to the individual metabolic response (glycaemia, HbA1c).<br />Glucovance 500 mg/5 mg may preferentially be used in patients inadequately controlled with Glucovance 500 mg/2.5 mg.<br />Adults with normal renal function (GFR &ge; 90 mL/min)<br />Initiation of treatment:<br />Treatment should be initiated with a dose of the combination product equivalent to previous individual doses of metformin and Glibenclamide; the dose being gradually increased depending on results on glycaemic parameters.</p><p>&nbsp;</p><p>Dose titration:<br />The dosage should be adjusted every 2 weeks or longer, by increments of 1 tablet, depending on glycaemia results.<br />A gradual increase in the dosage may aid gastrointestinal tolerance and prevent the onset of hypoglycaemia.<br />Maximum daily recommended dose:<br />&bull; The maximum daily recommended dose is 3 tablets of Glucovance 500 mg/5 mg.<br />&bull; In exceptional cases, an increase up to 4 tablets of Glucovance 500 mg/5 mg per day may be recommended.<br />&bull;<br />Combination with insulin therapy:<br />No clinical data are available on the concomitant use of this product with insulin therapy.<br />Renal impairment<br />A GFR should be assessed before initiation of treatment with metformin containing products and at least annually thereafter. In patients at an increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months.<br />The maximum daily dose of metformin should preferably be divided into 2-3 daily doses. Factors that may increase the risk of lactic acidosis (see 4.4) should be reviewed before considering initiation of metformin in patients with GFR &lt; 60 mL/min.<br />If no adequate strength of Glucovance is available, individual mono-components should be used instead of the fixed dose combination.</p><p>&nbsp;</p><p>GFR mL/min<br />Metformin<br />Glibenclamide<br />60-89<br />Maximum daily dose is 3000 mg.<br />Dose reduction may be considered in relation to declining renal function.<br />No dose reduction required.<br />45-59<br />Maximum daily dose is 2000 mg.<br />The starting dose is at most half of the maximum dose.<br />Maximum daily dose is 10.5 mg.<br />30-44<br />Maximum daily dose is 1000 mg.<br />The starting dose is at most half of the maximum dose.<br />Maximum daily dose is 10.5 mg. Initiation of therapy is not recommended due to the risk of hypoglycemia.<br />&lt; 30<br />Metformin / Glibenclamide are contraindicated</p><p>&nbsp;</p><p>Geriatric population:<br />The dosage of Glucovance should be adjusted depending on renal function parameters (start with 1 tablet of Glucovance 500 mg/2.5 mg); regular checks on the renal function are necessary (see section 4.4).<br />Patients aged 65 years and older: starting and maintenance doses of Glibenclamide must be carefully adjusted to reduce the risk of hypoglycaemia. Treatment should be started with the lowest available dose and increased gradually if necessary (see section 4.4).<br />Paediatric population:<br />Glucovance is not recommended for use in children (see section 5.1).<br />Method of administration<br />The dosage regimen depends on the individual posology:<br />&bull; Once a day, in the morning at breakfast, for a dosage of 1 tablet/day,<br />&bull; Twice a day, morning and evening, for a dosage of 2 or 4 tablets/day,<br />&bull; Three times a day, morning, noon and evening, for a dosage of 3 tablets/day.<br />The tablets should be taken with meals. The dosage regimen should be adjusted according to the individual eating habits. However, any intake must be followed by a meal with a sufficiently high carbohydrate content to prevent the onset of hypoglycaemic episodes.<br />When Glucovance is co-administered with a bile acid sequestrant, it is recommended that Glucovance should be administered at least 4 hours prior to the bile acid sequestrant in order to minimize the risk of reduced absorption (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • hypersensitivity to metformin, Glibenclamide or other Sulphonylureas(s) and sulphonamide(s) or to any of the excipients listed in section 6.1;
• type 1 diabetes (insulin-dependent diabetes), diabetic pre-coma;
• any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis);
• severe renal failure (GFR < 30 mL/min);
• acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock;
• disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as decompensated heart failure, respiratory failure, recent myocardial infarction, shock;
• hepatic insufficiency, acute alcohol intoxication, alcoholism;
• porphyria;
• lactation;
• in association with miconazole (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactic acidosis<br />Lactic acidosis, a very rare but serious metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis. Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.<br />In case of dehydration (severe diarrhoea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended.<br />Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin-treated patients. Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5).<br />Patients and/or care-givers should be informed of the risk of lactic acidosis. Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are decreased blood pH (&lt; 7.35), increased plasma lactate levels (&gt; 5 mmol/L) and an increased anion gap and lactate/pyruvate ratio.<br />Hypoglycaemia<br />As it contains a Sulphonylureas, Glucovance exposes the patient to a risk of onset of hypoglycaemic episodes. After treatment initiation, a progressive dose titration may prevent the onset of hypoglycaemia. This treatment should only be prescribed if the patient adheres to a regular meal schedule (including breakfast). It is important that carbohydrate intake is regular since the risk of hypoglycaemia is increased by a late meal, insufficient or unbalanced carbohydrate intakes. Hypoglycaemia is more likely to occur in case of energy-restricted diet, after intensive or prolonged exercise, when alcohol intake or during the administration of a combination of hypoglycaemic agents.<br />Diagnosis:<br />The symptoms of hypoglycaemia are: headache, hunger, nausea, vomiting, extreme tiredness, sleep disorder, restlessness, aggression, impaired concentration and reactions, depression, confusion, speech impediment, visual disturbances, trembling, paralysis and paraesthesia, dizziness, delirium, convulsions, somnolence, unconsciousness, superficial breathing and bradycardia. Due to a counter regulation caused by the hypoglycaemia sweating, fear, tachycardia, hypertension, palpitations, angina and arrhythmia can occur. These latter symptoms can be absent when the hypoglycaemia is developed slowly, in case of autonomic neuropathy or when the patients take beta-blocking agents, clonidine, reserpine, guanethidine or sympathomimetics.<br />Management of hypoglycaemia:<br />Moderate hypoglycaemic symptoms without loss of consciousness or neurological manifestations should be corrected by the immediate intake of sugar. An adjustment to the dosage and/or changes to meal patterns should be ensured. Severe hypoglycaemic reactions with coma, seizures or other neurological signs are also possible and constitute a medical emergency requiring immediate treatment with intravenous glucose once the cause is diagnosed or suspected, prior to prompt hospitalisation of the patient.</p><p>&nbsp;</p><p>reduce the risk of hypoglycaemic episodes. If the patient encounters repeated episodes of hypoglycemia, which are either severe or associated with unawareness of the situation, antidiabetic treatment options other than Glucovance should be taken into consideration.<br />Factors favouring hypoglycaemia:<br />&bull; concomitant administration of alcohol, especially combined with fasting,<br />&bull; refusal or (more particularly in elderly patients) inability of the patient to co-operate,<br />&bull; malnutrition, irregular meals, missed meals, fasting or changes to diet,<br />&bull; poor balance between physical exercise and carbohydrate intake,<br />&bull; renal failure,<br />&bull; severe liver failure,<br />&bull; overdose of Glucovance,<br />&bull; certain endocrine disturbances: thyroid insufficiency, pituitary and adrenal gland insufficiency,<br />&bull; concomitant administration of certain other drugs (see section 4.5).<br />Elderly patients:<br />Age 65 years and older has been identified as a risk factor for hypoglycaemia in patients treated with sulfonylureas. Hypoglycaemia can be difficult to recognize in the elderly. Starting and maintenance doses of Glibenclamide must be carefully adjusted to reduce the risk of hypoglycaemia (see section 4.2).<br />Renal and hepatic failure:<br />The pharmacokinetics and/or pharmacodynamics of Glucovance may be modified in patients with hepatic failure or severe renal failure. If hypoglycaemia occurs in such patients, it may be prolonged, and appropriate treatment must be initiated.<br />Patient information:<br />The risks of hypoglycaemia, its symptoms and its treatment, as well as its predisposing conditions, must be explained to the patient and his or her family. Similarly, the risk of lactic acidosis must be considered in the event of non-specific signs such as muscle cramps accompanied by digestive disorders, abdominal pain and severe asthenia, dyspnoea attributed to acidosis, hypothermia and coma.<br />In particular, the patient should be informed of the importance of adhering to a diet, following a programme of regular physical exercise and making regular checks on glycaemia.<br />Blood sugar imbalance<br />In case of surgery or any other cause of diabetic decompensation, temporary insulin therapy should be envisaged instead of this treatment.<br />The symptoms of hyperglycaemia are: increased urinating, raging thirst and a dry skin.<br />Cardiac function<br />Patients with heart failure are more at risk of hypoxia and renal insufficiency. In patients with stable chronic heart failure, Glucovance may be used with a regular monitoring of cardiac and renal function.<br />For patients with acute and unstable heart failure, Glucovance is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Renal function<br />GFR should be assessed before treatment initiation and regularly thereafter, see section 4.2. Metformin is contraindicated in patients with GFR &lt; 30 mL/min and should be temporarily discontinued in the presence of conditions that alter renal function, see section 4.3.<br />Administration of iodinated contrast agents<br />Intravascular administration of iodinated contrast agents may lead to contrast induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis. Glucovance should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.5.<br />Concomitant use of Glibenclamide with other medicinal products<br />The concomitant use of Glibenclamide with alcohol, phenylbutazone or danazol is not recommended (see section 4.5).<br />Surgery<br />Glucovance must be discontinued at the time of surgery under general, spinal or epidural anaesthesia. Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.<br />Other precautions<br />All patients should continue their diet, with a regular distribution of carbohydrate intake during the day. Overweight patients should continue their energy-restricted diet.<br />Regular physical exercise is as necessary as taking Glucovance.<br />The usual laboratory tests for diabetes monitoring (glycaemia, HbA1c) should be performed regularly,<br />Treatment of patients with G6PD-deficiency with Sulphonylureas agents can lead to haemolytic anaemia. Since Glibenclamide belongs to the chemical class of Sulphonylureas drugs, caution is recommended when using Glucovance in patients with G6PD-deficiency and a non-Sulphonylureas alternative may be considered.<br />Because this medicinal product contains lactose, it is contraindicated in case of congenital galactosemia, glucose and galactose malabsorption syndrome or in case of lactase deficiency.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contraindicated combination<br />Related to Glibenclamide<br />Miconazole (systemic route, or mucosal gel): Increase in the hypoglycaemic effect with possible onset of hypoglycaemic manifestations, or even coma (see section 4.3).<br />Combinations not recommended<br />Related to Sulphonylureas(s)<br />Alcohol:<br />Antabuse effect (intolerance to alcohol), notably for chlorpropamide, Glibenclamide, glipizide, tolbutamide.<br />Increase of the hypoglycaemic reaction (inhibition of compensation reactions), which may facilitate the onset of a hypoglycaemic coma (see section 4.4).<br />Avoid consumption of alcohol and alcohol-containing medications.<br />Phenylbutazone (systemic route):<br />Increase in the hypoglycaemic effect of Sulphonylureas(s) (displacement of Sulphonylureas(s) from protein-binding sites and/or decrease in their elimination). Preferably use another anti-inflammatory agent exhibiting fewer interactions, or else warn the patient and step up self-monitoring; if necessary, adjust the dosage during treatment with the anti-inflammatory agent and after its withdrawal.<br />Related to all antidiabetic agents<br />Danazol:<br />If the combination cannot be avoided, warn the patient and step up self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic treatment during treatment with danazol and after its withdrawal.</p><p>&nbsp;</p><p>Related to metformin<br />Alcohol:<br />Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in cases of fasting, malnutrition or hepatic impairment.<br />Iodinated contrast agents:<br />Glucovance must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.4.<br />Combinations requiring precautions<br />Related to all antidiabetic agents<br />Chlorpromazine:<br />At high dosages (100 mg per day of chlorpromazine), elevation in blood glucose (reduction in release of insulin).<br />Precaution for use: warn the patient and step up self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic treatment during treatment with the neuroleptic and after its withdrawal.</p><p>&nbsp;</p><p>Corticosteroids (glucocorticoids) and tetracosactides (systemic and local routes):<br />Elevation in blood glucose, sometimes accompanied by ketosis (decreased carbohydrate tolerance with corticosteroids).<br />Precaution for use: warn the patient and step up self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic during treatment with corticosteroids and after their withdrawal.<br />&beta;2-agonists:<br />Elevation in blood glucose due to the &beta;2-agonists.<br />Precaution for use: warn the patient, step up blood glucose monitoring and possibly transfer to insulin therapy.<br />Related to metformin<br />Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. When starting or using such products in combination with metformin, close monitoring of renal function is necessary.<br />Organic cation transporters (OCT)<br />Metformin is a substrate of both transporters OCT1 and OCT2.<br />Co-administration of metformin with<br />&bull; Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.<br />&bull; Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.<br />&bull; Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprime, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.<br />&bull; Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of metformin.<br />Caution is therefore advised, especially in patients with renal impairment, when these drugs are co-administered with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.<br />Related to Glibenclamide</p><p>Beta-blockers:<br />All beta-blockers mask some of the symptoms of hypoglycaemia: palpitations and tachycardia; Most non-cardio selective beta-blockers increase the incidence and severity of hypoglycaemia.<br />Warn the patient and step up blood glucose self-monitoring, especially at the start of treatment.<br />Angiotensin converting enzyme inhibitors (e.g. captopril, enalapril):<br />ACE inhibitors may decrease the blood glucose levels. If necessary, adjust the dosage of Glucovance during therapy with an ACE inhibitor and upon its discontinuation.<br />Fluconazole:<br />Increase in the half-life of Sulphonylureas with possible onset of hypoglycaemic manifestations.<br />Warn the patient and step up blood glucose self-monitoring, and possibly adjust the dosage of the antidiabetic treatment during treatment with fluconazole and after its withdrawal.<br />Bosentan:<br />Risk of decreased hypoglycaemic effect of Glibenclamide because bosentan reduces the plasma concentration of Glibenclamide. An increased risk of liver enzyme elevations was reported in patients receiving Glibenclamide concomitantly with bosentan.</p><p>Warn the patient, set-up monitoring of glycaemia and liver enzymes and adjust the dosage of the antidiabetic treatment if necessary.<br />Bile acid sequestrants:<br />When co-administered simultaneously the plasma concentration of Glibenclamide is reduced which may lead to a reduced hypoglycaemic effect. This effect was not observed if Glibenclamide is given in a certain period of time before taking the other medicine. It is recommended that Glucovance should be administered at least 4 hours prior a bile acid sequestrant.<br />Other interaction: combination to be taken into account:<br />Related to Glibenclamide<br />Desmopressin:<br />Reduction in antidiuretic activity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />No preclinical and clinical data on exposed pregnancies are available for Glucovance.<br />Risk related to diabetes<br />When uncontrolled, diabetes (gestational or permanent) gives rise to an increase in congenital abnormalities and perinatal mortality. Diabetes must be controlled as far as possible during the period of conception in order to reduce the risk of congenital abnormalities.<br />Risk related to metformin (see section 5.3)<br />Animal studies do not indicate harmful effects with respect to pregnancy, embryonic or fetal development, parturition or postnatal development.<br />A limited amount of data from the use of metformin in pregnant women does not indicate an increased risk of congenital abnormalities.<br />Risk related to Glibenclamide (see section 5.3)<br />Studies in animals have shown no evidence of teratogenic activity. In the absence of a teratogenic effect in animals, foetal malformation in humans is not to be expected since to date, substances known to cause malformation in humans have proved to be teratogenic in well-conducted animal studies in two species.<br />In clinical practice, there are currently no relevant data on which to base an evaluation of potential malformation or fetotoxicity due to Glibenclamide when administered during pregnancy.<br />Management<br />Adequate blood glucose control allows pregnancy to proceed normally in this category of patients. Glucovance must not be used for the treatment of diabetes during pregnancy.<br />It is imperative that insulin be used to achieve adequate blood glucose control. It is recommended that the patient be transferred from oral antidiabetic therapy to insulin as soon as she plans to become pregnant or if pregnancy is exposed to this medicinal product. Neonatal blood glucose monitoring is recommended.</p><p>Breast-feeding<br />Metformin is excreted into human breast milk. No adverse effects were observed in breastfed newborns/infants of mothers treated with metformin alone. However, in humans, in the absence of data concerning passage of Glibenclamide into breast milk, and in view of the risk of neonatal hypoglycaemia, this medicinal product is contraindicated in the event of breast-feeding.<br />Fertility<br />Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose based on body surface area comparisons.<br />Fertility of male or female rats was unaffected by Glibenclamide when administered orally at dose of 100 and 300 mg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be alerted to the symptoms of hypoglycaemia and should be advised to exercise caution when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During treatment initiation, the most common adverse reactions are nausea, vomiting, diarrhoea, abdominal pain and loss of appetite which resolve spontaneously in most cases. To prevent them, it is recommended to take Glucovance in 2 or 3 daily doses and to increase slowly the doses.<br />Transient visual disturbances may occur at the start of treatment due to a decrease in glycaemia levels.<br />The following adverse reactions may occur under treatment with Glucovance. Frequencies are defined as follows: very common: &gt;1/10; common &ge;1/100, &lt;1/10; uncommon: &ge;1/1,000, &lt;1/100; rare &ge;1/10,000, &lt;1/1,000; very rare &lt;1/10,000.<br />Blood and lymphatic system disorders:<br />These are reversible upon treatment discontinuation.<br />Rare: Leukopenia, thrombocytopenia.<br />Very rare: Agranulocytosis, haemolytic anaemia, bone marrow aplasia and pancytopenia.<br />Metabolism and nutrition disorders:<br />Hypoglycaemia (see section 4.4).<br />Uncommon: Crises of hepatic porphyria and porphyria cutanea.<br />Very rare: Lactic acidosis (see section 4.4).<br />Decrease of vitamin B12 absorption with decrease of serum levels during long-term use of metformin. Consideration of such aetiology is recommended if a patient presents with megaloblastic anaemia.<br />Disulfiram-like reaction with alcohol intake.<br />Nervous system disorders:<br />Common: Taste disturbance.<br />Eye disorders:<br />Transient visual disturbances may occur at the start of treatment due to a decrease in glycaemia levels.</p><p>Gastrointestinal disorders:<br />Very common: Gastrointestinal disorders such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite. These undesirable effects occur more frequently during treatment initiation and resolve spontaneously in most cases. To prevent them, it is recommended that Glucovance be taken in 2 or 3 daily doses. A slow increase of the dose may also improve gastrointestinal tolerability.<br />Skin and subcutaneous tissue disorders:<br />A cross reactivity to sulphonamide(s) and their derivatives may occur.<br />Rare: Skin reactions such as pruritus, urticaria, maculopapular rash.<br />Very rare: Cutaneous or visceral allergic angiitis, erythema multiforme, exfoliative<br />dermatitis, photosensitization, urticaria evolving to shock.<br />Hepatobiliary disorders:<br />Very rare: Liver function test abnormalities or hepatitis requiring treatment discontinuation<br />Investigations:<br />Uncommon: Average to moderate elevations in serum urea and creatinine concentrations.<br />Very rare: Hyponatremia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose may precipitate hypoglycaemia due to the presence of the Sulphonylureas (see section 4.4).<br />High overdose or the existence of concomitant risk factors may lead to lactic acidosis due to the presence of metformin (see section 4.4). Lactic acidosis is a medical emergency and must be treated in hospital. The most effective treatment is to remove lactate and metformin by haemodialysis.<br />The plasma clearance of Glibenclamide may be prolonged in patients suffering from liver disease. Since Glibenclamide is extensively bound to proteins, it is not eliminated by dialysis</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Biguanides and sulphonamide(s) in combination. ATC code: A10BD02<br />Metformin is a biguanide with antihyperglycemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.<br />Metformin may act via 3 mechanisms:<br />(1) by reducing hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis<br />(2) in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation<br />(3) and by delaying intestinal glucose absorption.<br />Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase. Metformin increases the transport capacity of all types of membrane glucose transporters (GLUT).<br />In humans, independently of its action on glycaemia, metformin has favourable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: metformin reduces total cholesterol, LDL-cholesterol and triglyceride levels. In clinical trials conducted so far with combination therapy with metformin and Glibenclamide, these favourable effects on lipid metabolism have not been shown.<br />Glibenclamide is a second generation Sulphonylureas with a medium half-life: it causes acute lowering of blood glucose by stimulating the release of insulin by the pancreas, this effect being dependent on the presence of functioning beta cells in the islets of Langerhans.<br />The stimulation of insulin secretion by Glibenclamide in response to a meal is of major importance.<br />The administration of Glibenclamide to diabetics induces an increase in the postprandial insulin-stimulating response. The increased postprandial responses in insulin and C-peptide secretion persist after at least 6 months of treatment.<br />Metformin and Glibenclamide have different mechanisms and sites of action, but their action is complementary. Glibenclamide stimulates the pancreas to secrete insulin, while metformin reduces cell resistance to insulin by acting on peripheral (skeletal muscle) and hepatic sensitivity to insulin.<br />Results from controlled, double blind clinical trials versus reference products in the treatment of type 2 diabetes inadequately controlled by monotherapy with metformin or Glibenclamide combined with diet and exercise, have demonstrated that the combination had an additive effect on glucose regulation.</p><p>Paediatric population:<br />In a 26-week, active controlled, double-blind, clinical study performed in 167 paediatric patients aged 9 to 16 years with type 2 diabetes not adequately controlled with diet and exercise, with or without an oral antidiabetic treatment, a fixed combination of metformin hydrochloride 250 mg and Glibenclamide 1.25 mg was not shown more effective to either metformin hydrochloride or Glibenclamide in reducing HbA1c from baseline. Therefore, Glucovance should not be used in paediatric patients.</p><p>Related to the combination<br />The bioavailability of metformin and Glibenclamide in the combination is similar to that noted when one tablet of metformin and one tablet of Glibenclamide are taken simultaneously. The bioavailability of metformin in the combination is unaffected by the ingestion of food. The bioavailability of Glibenclamide in the combination is unaffected by the ingestion of food, but the absorption speed of Glibenclamide is increased by eating.<br />Related to metformin<br />Absorption:<br />After an oral dose of metformin tablet, maximum plasma concentration (Cmax) is reached in approximately 2.5 hours (tmax). Absolute bioavailability of a 500 mg or 850 mg metformin tablet is approximately 50-60% in healthy subjects. After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.<br />After oral administration, metformin absorption is saturable and incomplete. It is assumed that the pharmacokinetics of metformin absorption is non-linear. At the usual metformin doses and dosing schedules, steady state plasma concentrations are reached within 24 to 48 hours and are generally less than 1 &mu;g/ml. In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 5 &mu;g/ml, even at maximum doses.<br />Distribution:<br />Plasma protein binding is negligible. Metformin partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean volume of distribution Vd ranged from 63 to 276 l.<br />Biotransformation:<br />Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.<br />Elimination:<br />Renal clearance of metformin is &gt; 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours.<br />When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in plasma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Related to Glibenclamide<br />Absorption:<br />Glibenclamide is very readily absorbed (&gt; 95%) following oral administration. The peak plasma concentration is reached in about 4 hours.<br />Distribution:<br />Glibenclamide is extensively bound to plasma albumin (99%), which may account for certain drug interactions.<br />Biotransformation:<br />Glibenclamide is completely metabolised in the liver to two metabolites. Hepatocellular failure decreases Glibenclamide metabolism and appreciably slows down its excretion.<br />Elimination:<br />Glibenclamide is excreted in the form of metabolites via biliary route (60%) and urine (40%), elimination being complete within 45 to 72 hours. Its terminal elimination half-life is 4 to 11 hours.<br />Biliary excretion of the metabolites increases in cases of renal insufficiency, according to the severity of renal impairment until a creatinine clearance at 30 ml/min. Thus, Glibenclamide elimination is unaffected by renal insufficiency as long as the creatinine clearance remains above 30 ml/min.<br />Paediatric population<br />There were no differences in pharmacokinetics of Glibenclamide and metformin between paediatric patients and weight-and gender-matched healthy adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No preclinical studies have been performed on the combination product. Preclinical evaluation of the constituents metformin and Glibenclamide revealed no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity and carcinogenic potential.<br />Animal studies on metformin and Glibenclamide do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/ foetal development, parturition or postnatal development. (see section 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core<br />Microcrystalline cellulose<br />Sodium croscarmellose<br />Povidone K30<br />Magnesium stearate</p><p>&nbsp;</p><p>Film-coating<br />Opadry 31-F-22700 (yellow) (lactose monohydrate, hypromellose, titanium dioxide (E171), macrogol, yellow iron oxide (E172), red iron oxide (E172), Quinoline Yellow Lake (E104)).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>What Glucovance looks like and contents of the pack<br />Glucovance 500 mg/2.5 mg tablets are orange capsule-shaped, biconvex, film-coated tablets with<br />&ldquo;2.5&rdquo; engraved on one side.<br />Glucovance 500 mg/5 mg tablets are yellow capsule-shaped, biconvex, film-coated tablets with &ldquo;5&rdquo;<br />engraved on one side.<br />The tablets are supplied in clear or opaque blister packs containing 20, 28, 30, 50, 56, 60, 84, 90, 100,<br />120, 180 or 600 tablets (PVC/Aluminium). Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MERCK SANTE S.A.S
37, RUE SAINT ROMAIN
69008 LYON – FRANCE
PACKED BY RIYADH PHARMA
MEDICAL & COSMETIC PRODUCTS CO. LTD.
RIYADH, SAUDI ARABIA.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                15 April 2019 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>